Moksifloksacin Stada (Moxifloxacin)

Moxifloxacin, the active ingredient in Moksifloksacin Stada, is a fluoroquinolone antibiotic presented as an oral tablet for oral use. It treats a variety of bacterial infections, including respiratory, sinus, skin and intra‑abdominal infections, in adult and pediatric patients when prescribed by a qualified healthcare professional.

GNH USA supplies Moksifloksacin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company consistently adheres to stringent quality standards and provides regulatory‑approved products to meet global demand throughout.

Moxifloxacin is a fluoroquinolone antibiotic used to treat infections caused by susceptible bacteria across several organ systems.

- Community-acquired bacterial pneumonia: provides effective eradication of the pathogen, improving respiratory function and reducing fever. - Acute bacterial sinusitis: alleviates sinus inflammation and clears infection, leading to symptom relief. - Acute bacterial exacerbation of chronic bronchitis: reduces bacterial load, helping to restore normal airway clearance. - Skin and skin structure infections: combats Gram‑positive and Gram‑negative organisms, promoting wound healing. - Intra-abdominal infections: targets mixed bacterial flora, supporting recovery after surgical or medical management.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Headache - Rash

Serious or Rare Side Effects: - Tendon rupture or inflammation - QT interval prolongation leading to arrhythmia - Severe allergic reactions such as anaphylaxis - Clostridioides difficile‑associated colitis - Peripheral neuropathy - Hepatic enzyme elevation

When prescribing or dispensing Moksifloksacin Stada, consider the following precautions: - Assess renal and hepatic function: adjust therapy if impairment is present. - Avoid use in patients with a history of tendon disorders: risk of tendon rupture is increased. - Monitor cardiac status: watch for QT prolongation, especially with other QT‑prolonging agents. - Use with caution in pregnancy and breastfeeding: safety data are limited. - Counsel patients to avoid concomitant NSAIDs or corticosteroids when possible: may heighten tendon injury risk. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Moksifloksacin Stada can interact with several medicines; awareness of major and moderate interactions helps ensure safe use.

Major Interactions (Avoid): - Antacids or supplements containing aluminum, magnesium, calcium, or iron: markedly reduce oral absorption. - Warfarin: may potentiate anticoagulant effect and increase INR. - Theophylline: increased plasma concentrations leading to toxicity.

Moderate Interactions (Monitor Closely): - Corticosteroids: combined use raises risk of tendon rupture. - Other QT‑prolonging drugs (e.g., macrolides, fluoroquinolones): additive effect on cardiac rhythm. - Diabetes medications (e.g., insulin, sulfonylureas): may affect glycemic control.